Nanosonics Limited · ASX:NAN
Nanosonics — Investor Presentation (August 2009)
17 slides from Nanosonics's investor presentation, Aug 24, 2009
Slide 1: Investor Presentation
For personal use only Investor Presentation David Radford - Executive Director and CEO August 2009
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, fina
Slide 3: Key Investment Highlights
Key Investment Highlights For personal use only Milestones FY2009 • Succesful transition from R&D to commercial entity • Production and Sales commenced • Extensive distribution network appointed • TGA approval • Devices installed in Australia and Europe • 510(k) application to USA FDA • Trophon EPR
Slide 4: Nanosonics at a glance
Nanosonics at a glance For personal use only Category Date Amount Total shares on issues @ 20 August 2009 196 million Share price @ 20 August 2009 A$ 0.43 Market capitalisation @ 20 August 2009 A$ 84.3 million Cash on hand @ 30 June 2009 A$ 13.8 million
Slide 5: Financial results FY2009
Financial results FY2009 For personal use only The Company is well positioned for expected growth in FY2010 A$’000 Sales 309 Less cost of Sales -121 Government grants received 150 Interest Income 1,194 Total revenue 1,532 Expenses -10,286 Cash Assets 13,881
Slide 6: Our vision: Commercialising innovative solutions to global challenges
Our vision:Commercialising innovative For personal use only solutions to global challenges “At Nanosonics our goal is simple, to safeguard the health and wellbeing of individuals, communities and environments by commercialising new standards in disinfection and sterilisation technologies” David Radf
Slide 7: Trophon EPR - A breakthrough in the world of medical disinfection
Trophon EPR - A breakthrough in the world For personal use only of medical disinfection “The Trophon EPR will make the task of disinfecting ultrasound transducers significantly faster, safer and more convenient and it is easily integrated into current medical practices and procedures” Dr Michael Coo
Slide 8: Trophon - A breakthrough in the world of medical disinfection
Trophon - A breakthrough in the world of For personal use only medical disinfection Global market opportunity The US Centre for Disease Control (CDC) Recommends the use of hydrogen peroxide for high-level disinfection of intra- • 0.5 B Ultrasound procedures cavity probes because it is “not toxic to
Slide 9: Market opportunity
Market opportunity For personal use only Total Total Country/ Radiology O&G Other targeted available Region intracavity intracavity targeted market market ANZ 0.5M 1M 0.2M 1.7M 5.8M Europe 7M 16M 3M 26M 70M Canada 0.4M 0.9M 0.2M 1.5M 3.6M US 7M 11M 9M 27M 87M Asia 8.2M 17M 22M 47.2M 215M Japan 3.4M
Slide 10: Customer feedback
Customer feedback For personal use only “The Trophon greatly improves our workflow” David Singe, Radiographer The Trophon EPR has significantly aided the workflow of the ultrasound department. The product has directly been installed at the point of care and is accompanying the ultrasound machine in
Slide 11: Controlled roll-out
Controlled roll-out For personal use only • Targeted 6 months field experience prior to rapid expansion • Pricing and marketing pitch validated and confirmed • Service model developed - incremental revenue stream • Quality Management System supporting roll-out
Slide 12: Distribution strategy
Distribution strategy For personal use only • Local distribution partners appointed with recognised expertise in the ultrasound market • OEMs have direct access to product across all markets • Attractive margins through the supply chain Appointed Appointed In progress Australia UK Asia Region New Ze
Slide 13: Regulatory update
Regulatory update For personal use only • TGA audit August 2009 • TUV audit September 2009 • USA FDA submission is progressing • Japan lodgement targeted Q3 FY2010
Slide 14: Research and Development
Research and Development For personal use only NanoNebulant and associated technologies are transferable and highly scalable to other applications Food applications Platform technology Scaleable Room / Industrial Cost effective Medical /Healthcare Environmentally friendly
Slide 15: R&D projects
R&D projects For personal use only • Success of the NanoNebulant platform has attracted discussion with a number of significant global corporations • Continued investment in new product opportunities and pipeline development • Leveraging current NanoNebulant platform technology • Endoscope/TEE probe
Slide 16: Summary
Summary For personal use only • Current infection control challenges driving market acceptance • Staged roll-out proceeding to plan • Trophon EPR demonstrating proof of concept • Strong cash position enabling the Company to execute current strategies including significant R&D investments • Company w
Slide 17: For personal use only
i ex, AjUO OSN |CUOSIJOCd JOS